What do systematic reviews say?

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 119 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 182 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 184 participants
  Moderate

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 121 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with another intervention (education, joint aids, or relaxation) plus… (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.13, 5.94]
  7 studies · 317 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with placebo plus usual pharmacological care (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 2.73 [0.34, 22.16]
  1 study · 21 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 104 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 96 participants
  Low

Antiplatelet drug vs control

Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.95 [0.91, 0.99]
  7 studies · 42034 participants
  Moderate

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.93 [0.87, 0.98]
  10 studies · 41929 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.71 [0.53, 0.96]
  7 studies · 41042 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.79 [0.7, 0.88]
  9 studies · 41652 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 1.18 [0.97, 1.44]
  9 studies · 41652 participants
  Very low